louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06336694: A Deep Learning Radiomics Model for Predicting Occult Peritoneal Metastases of Pancreatic Adenocarcinoma
Official title: Development and Validation of a Deep Learning Radiomics Model With Clinical-radiological Characteristics for the Identification of Occult Peritoneal Metastases in Patients With Pancreatic Ductal Adenocarcinoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatic Neoplasms
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2024-03-29
Enrollment: 302
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with suspected pancreatic tumors who had undergone contrast-enhanced CT and pathological examinations were screened at Center 1 between January 2012 and October 2022 and Center 2 between January 2014 and October 2021.

Brief summary: Occult peritoneal metastases (OPM) in patients with pancreatic ductal adenocarcinoma (PDAC) are frequently overlooked during imaging. We aimed to develop and validate a CT-based deep learning-based radiomics (DLR) model with clinical-radiological characteristics to identify OPM in patients with PDAC before treatment.

Detailed description: This retrospective, bicentric study included 302 patients with PDAC (training: n = 167, OPM-positive, n=22; internal test: n = 72, OPM-positive, n=9: external test, n=63, OPM-positive, n=9) who had undergone baseline CT examinations between January 2012 and October 2022. Handcrafted radiomics (HCR) and DLR features of the tumor and HCR features of peritoneum were extracted from CT images. Mutual information and least absolute shrinkage and selection operator algorithms were used for feature selection. A combined model, which incorporated the selected clinical-radiological, HCR, and DLR features, was developed using a logistic regression classifier using data from the training cohort and validated in the test cohorts.

Eligibility criteria: Inclusion Criteria:

Patients with suspected pancreatic tumors who underwent contrast enhanced CT and pathological examinations at Center 1 and Center 2 were eligible for inclusion in this study.

Exclusion Criteria:

* (a) pathologically diagnosed PDAC by pathology, (b) time intervals between contrast-enhanced CT and pathology less than 2 weeks; (c) history of pancreatic surgery, (d) history of pancreatic malignancy, and (e) poor CT image quality that undermined peritoneal lesion assessment

Primary outcomes:
measure: diagnosed with peritoneal metastases
timeFrame: immediately after the surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Shi Siya
state: Guangdong
Study officials:
affiliation: First Affiliated Hospital, Sun Yat-Sen University
name: Shi-Ting Feng, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02376894: An Epidemiological Survey of Cancer-related Fatigue Among Taiwanese Cancer Patients
Official title: An Epidemiological Survey of Cancer-related Fatigue Among Taiwanese Cancer Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Lead sponsor: Taiwan Cancer Palliative Medicine
Sponsor class: OTHER
Collaborators: name: National Taiwan University Hospital
name: Shin Kong Wu Ho-Su Memorial Hospital
name: Tri-Service General Hospital
name: Changhua Christian Hospital
name: National Cheng-Kung University Hospital
name: Chung Shan Medical University
name: Kaohsiung Veterans General Hospital.
name: Taipei Veterans General Hospital, Taiwan
name: Taipei Medical University Hospital
name: Taipei Medical University Shuang Ho Hospital
name: Taipei Medical University WanFang Hospital
name: China Medical University Hospital
name: Mackay Memorial Hospital
name: Far Eastern Memorial Hospital
name: Chang Gung Memorial Hospital
name: Chiayi Christian Hospital
name: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
name: Taichung Tzu Chi Hospital
name: Chi Mei Medical Hospital
First posted: 2015-03-03
Enrollment: 1211
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: cancer patient

Brief summary: The aim of this study is to examine the prevalence, severity, impacts and managements of CRF among Taiwanese cancer patients.

Detailed description: The cross-sectional survey is conducted at oncology inpatients unit and outpatients clinics of hospitals in Taiwan. Furthermore, the results will elucidate not only the epidemiology of CRF in Taiwan, but will supply physicians with more understanding about CRF, and help them to enhance the quality on cancer care to being perfected in the future.

Eligibility criteria: Inclusion Criteria:

* (1) Patients who signed the informed consent form
* (2) The age of eligible patients should be \> 20 years old.
* (3) Inpatients or outpatients who have been given a diagnosis of cancer
* (4) Able to communicate verbally and completely fill out the questionnaires

Exclusion Criteria:

* Patients who have been given a diagnosis of cognitive impairment are unable to complete the questionnaires

Primary outcomes:
measure: Cancer-related fatigue evaluation
timeFrame: 30 minuts
measure: Symptoms and Quality of Life Assessments
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University Hospital
Study officials:
References:
Clinical trial NCT02285894: Can 10 Seconds Inspiratory Hold Open Atelectasis in Mechanically Ventilated Patients?
Official title: Can 10 Seconds Inspiratory Hold Open Atelectasis in Mechanically Ventilated Patients? A Pilot Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Atelectasis
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: University of Oslo
First posted: 2014-11-07
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study evaluates whether sustaining inspiratory pressure for 10 seconds at a time can open collapsed lung areas in non-dependant regions of the lung in mechanically ventilated patients.

Detailed description: Collapse of lung volume, atelectasis, is a common complication in sedated and mechanically ventilated patients. In adults the atelectasis occur mainly in the dependant areas of the lung. In this study the investigators examine whether these atelectasis can be opened by repeatedly sustaining the inspiratory pressure for 10 seconds when the patient has been positioned so that the atelectasis is located in a non-dependant position. Furthermore, the investigators examine how many times the inspiratory pressure needs to be sustained before the atelectasis is opened and at what pressure.

Eligibility criteria: Inclusion Criteria:

* Continuously or intermittently mechanically ventilated with artificial airway (endotracheal tube or tracheostomy tube)
* Pressure controlled or pressure supported ventilator mode
* PEEP ≤ 12 cm H2O, registered peak pressure ≤ 32 cm H2O
* Non-ventilated lung regions according to E.I.T. measurements
* Richmond Agitation Score 0 -(-5)
* Circulatory stable or stabilized

Exclusion Criteria:

* Pregnancy
* BMI \> 50
* Pacemaker or other electrically active implants
* Skin lesions, wounds or bandages on chest area where E.I.T. belt needs to be placed
* Undrained pneumothorax
* Pulsating air-mattress
* Unstable skeletal injury to spinal column
* Recent brain injury or spinal chord injury
* Recent injury to heart, to major blood vessels in chest, to major airways or to the oesophagus.

Primary outcomes:
measure: Ventilation in previously non-ventilated lung tissue
timeFrame: During intervention and for 30 minutes after ended intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo university Hospital, Ullevål
Study officials:
affiliation: University of Oslo
name: Nina K Vøllestad, Dr.Scient
role: PRINCIPAL_INVESTIGATOR
affiliation: Oslo University Hospital
name: Harald Noddeland, PhD, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06280794: Efficacy of Laser Acupuncture for Idiopathic Bell's Palsy
Official title: Efficacy of Laser Acupuncture for Idiopathic Bell's Palsy: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Bell's Palsy
Keywords: Idiopathic facial paralysis
Bell's palsy
Laser acupuncture
photobiomodulation
RCT
Lead sponsor: Beijing Tongren Hospital
Sponsor class: OTHER
First posted: 2024-02-28
Enrollment: 336
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Objective:

Bell's palsy is characterized by acute, unilateral onset that compromises function and esthetics, exerting a considerable impact on the social, professional, and psychological aspects of the lives of affected individuals. The objective of this study was to determine whether laser acupuncture therapy could relieve symptoms in patients with Bell's palsy in 8 weeks.

Methods:

This study was randomized controlled trial including 360 patients that undergoing Bell's palsy. All the patients received oral Prednisolone. Patients were assigned to the laser acupuncture (LA) group, Sham LA group and control group, with 120 patients in each group. LA group and Sham LA group were received 4 weeks of Laser treatment (3 times per week).

Clinical outcome measure comprised the House-Brackmann grading system, Facial Clinimetric Evaluation Scale (FaCE), Sunnybrook facial grading scale (SBFG), Facial Disability Index (FDI) and Facial Clinimetric Evaluation Scale (FaCE Scale) All the measurements were collected at the baseline, weeks 2, 4, 6, 8, 12 and 24.


Eligibility criteria: Inclusion Criteria:

* 1. Patients diagnosed with idiopathic Bell's Palsy 2.Patients were eligible if they were graded at House-Brackmann grade (HB) 3 or higher.

Exclusion Criteria:

- 1.Serious mental illness or social problems, and neurological disorders, and systemic diseases, such as malignant tumors, and other serious consumptive diseases.

2. Planning for pregnancy, those in pregnancy, or those who were lactating. 3.Bell's Palsy patients who have a disease course of more than 8 weeks.

Primary outcomes:
measure: House Brackmann Grading System (HB)
timeFrame: Baseline, weeks 2, 4, 6, 8, 12 and 24
Secondary outcomes:
measure: Sunnybrook Facial Grading Scale (SB Grading)
timeFrame: Baseline, weeks 2, 4, 6, 8, 12 and 24
measure: Facial Disability Index (FDI)
timeFrame: Baseline, weeks 2, 4, 6, 8, 12 and 24
measure: Facial Clinimetric Evaluation Scale (FaCE Scale)
timeFrame: Baseline, weeks 2, 4, 6, 8, 12 and 24
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing TongRen Hospital, Capital Medical University
Study officials:
References:
Clinical trial NCT03611894: Comparison of the Radiological Pattern Between the Cerebral Stroke of Arterial and Venous Origin
Official title: Comparison of the Radiological Pattern Between the Cerebral Stroke of Arterial and Venous Origin
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stroke
Superior Sagittal Sinus Thrombosis
Venous Thromboses
Keywords: RMI
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2018-08-02
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The investigators want to include consecutively hospitalized patients with CVT and parenchymal lesions on magnetic resonance imaging.

Brief summary: There are few published data on the patterns of parenchymal imaging abnormalities in a context of cerebral venous thrombosis (CVT). The objectives of the present study were to describe the patterns of parenchymal lesions associated with CVT and to determine the lesion sites.


Eligibility criteria: Inclusion Criteria:

* hospitalized patients with CVT
* parenchymal lesions on magnetic resonance imaging

Exclusion Criteria:

* No CVT

Primary outcomes:
measure: patterns
timeFrame: 0
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens
city: Rouen
country: France
facility: CHU Rouen
Study officials:
affiliation: CHU Amiens
name: Audrey Arnoux, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05396794: Bariatric Education for Women With Obesity and Endometrial Cancer
Official title: Bariatric Surgery Among Women With Obesity and Low Risk Endometrial Cancer: A Pilot Study
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Obesity
Endometrial Cancer
Bariatric Surgery Candidate
Keywords: bariatric surgery
endometrial cancer
obesity
Lead sponsor: University of Oklahoma
Sponsor class: OTHER
First posted: 2022-05-31
Enrollment: 26
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women with endometrial cancer with obesity who are receiving care at the Stephenson Cancer Center will be considered for inclusion. All patients regardless of race, ethnicity, or socioeconomic status will be included without discrimination.

Brief summary: The purpose of this study is to examine whether a standardized video education tool will improve knowledge regarding obesity and bariatric surgery and increase bariatric surgery referrals for obese women with endometrial cancer.

Detailed description: An estimated 50% of all endometrial cancer cases are associated with obesity. Bariatric surgery has been shown to reduce the risk of hormone-related cancers, including endometrial cancer, by up to 70-80%. This prospective, study of 80 patients will be randomized to either a standard education for weight loss provided by their oncologist or a standard education plus a 15-minute video with information regarding obesity, relationship of obesity and endometrial cancer, and the safety and benefits of bariatric surgery.

Eligibility criteria: Inclusion Criteria:

* Adults aged 18-80 with class II or greater obesity (BMI ≥ 35)
* Have pathologically-confirmed endometrial cancer
* Have completed initial therapy (e.g. surgery, hormonal therapy, vaginal cuff brachytherapy, or a combination of these modalities) and require no further interventions related to cancer care. Patients taking hormonal therapy as part of cancer treatment may be included.

Exclusion Criteria:

* Under the age of 18 or over the age of 80
* Have previously undergone bariatric surgery
* Requires ongoing cancer treatment with chemotherapy or whole pelvic radiation.
* Poor surgical candidate secondary to comorbidities or performance status.

Primary outcomes:
measure: Proportion of patient's obesity relevant knowledge pre- and post-education intervention
timeFrame: 6 Months
measure: Proportion of patients who chose to take part in bariatric surgery.
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: Stephenson Cancer Center
state: Oklahoma
Study officials:
affiliation: University of Oklahoma Stephenson Cancer Center
name: Laura L Holman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00851994: Urine Proteome of Patients Having Surgery
Official title: Urine Proteome of Patients Undergoing Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgery
Keywords: Patients having surgery
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2009-02-26
Enrollment: 274
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients having surgery.

Brief summary: The investigators are measuring novel proteins in the urine of patients having surgery.


Eligibility criteria: Inclusion Criteria:

* Patients \> 18 years of age
* Undergoing surgery

Exclusion Criteria:

* No formal exclusion criteria

Primary outcomes:
measure: Changes in urine proteins after surgery.
timeFrame: Pre-op, intraoperative, post operatively (1-6 months)
Secondary outcomes:
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Barnes Jewish Hospital
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Jerry Morrissey, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hu R, Gupta R, Wang Z, Wang C, Sun H, Singamaneni S, Kharasch ED, Morrissey JJ. Bioplasmonic paper-based assay for perilipin-2 non-invasively detects renal cancer. Kidney Int. 2019 Dec;96(6):1417-1421. doi: 10.1016/j.kint.2019.08.020. Epub 2019 Sep 3.
citation: Morrissey JJ, Mobley J, Figenshau RS, Vetter J, Bhayani S, Kharasch ED. Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer. Mayo Clin Proc. 2015 Jan;90(1):35-42. doi: 10.1016/j.mayocp.2014.10.005.
citation: Morrissey JJ, Kharasch ED. The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma. J Urol. 2013 May;189(5):1913-20. doi: 10.1016/j.juro.2012.11.034. Epub 2012 Nov 12.
citation: Morrissey JJ, London AN, Lambert MC, Kharasch ED. Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma. Am J Nephrol. 2011;34(5):391-8. doi: 10.1159/000330851. Epub 2011 Sep 7.
citation: Morrissey JJ, London AN, Luo J, Kharasch ED. Urinary biomarkers for the early diagnosis of kidney cancer. Mayo Clin Proc. 2010 May;85(5):413-21. doi: 10.4065/mcp.2009.0709. Epub 2010 Apr 7.
Clinical trial NCT04326894: Methorexate and Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain Reduction
Physical Function Improvement
Keywords: methotrxate, knee osteoarthritis, inflammation, pain, function
Lead sponsor: University of Alexandria
Sponsor class: OTHER
First posted: 2020-03-30
Enrollment: 128
Sex: ALL
Minimum age (years): 60
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Osteoarthritis (OA) is considered a complex, multifactorial disease leading to considerable pain and functional disability amongst older adults in particular.Synovial inflammation and proliferation has emerged as a key component of OA and as a potential predictor of worsening disease. Methotrexate (MTX) is widely used in the treatment of all inflammatory rheumatic diseases. Accordingly, the aim of the present study is to assess the efficacy of methotrexate (MTX) in decreasing pain and inflammation in symptomatic knee OA.

128 patients with clinical and radiographic criteria of primary knee OA pain,were recruited. Patients meeting the eligibility criteria are randomized in a 1:1 ratio to receive either 25mg/week oral MTX (n=64) or placebo (n=64) together with their usual therapy provided the dosages are kept constant for 32 weeks. The primary outcome measure is pain reduction and secondary outcome measures is improvement in physical function scores.

Keywords:

methotrexate knee osteoarthritis inflammation pain reduction physical funtion


Eligibility criteria: Inclusion Criteria:

* primary knee osteoarthritis
* synovitis
* pain

Exclusion Criteria:

* other inflammatory conditions
* hepatic insufficiency
* renal insufficiency

Primary outcomes:
measure: Pain reduction
timeFrame: 8 months
Secondary outcomes:
measure: Physical function improvement
timeFrame: 8 months
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Faculty of Medicine
Study officials:
References:
Clinical trial NCT06113094: Cryoablation for Advanced and Refractory Desmoid Tumors
Official title: Cryoablation for Advanced and Refractory Desmoid Tumors
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Desmoid Tumors
Keywords: Desmoid tumors
Fibromatosis
Invasive tumors
Radiotherapy
Cryoablation
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-11-02
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient (≥18 years old) having undergone cryoablation for an advanced desmoid tumor refractory to medical treatment

Brief summary: Desmoid tumors, also called aggressive fibromatosis, are rare, locally invasive tumors with no potential for metastasis. The incidence is approximately 2 to 4 per million per year in the general population. The "watch and wait" policy is the standard of care for newly diagnosed patients in Europe. Patients who progress have first-line medical treatment, surgery is no longer the treatment because there is a high rate of recurrence (\> 60%) and radiotherapy is not very suitable because the patients are often young and the tumors are large. Cryoablation seems to be an effective therapeutic option that should be evaluated.


Eligibility criteria: Inclusion criteria:

* Adult patient (≥18 years old)
* Having undergone cryoablation for an advanced desmoid tumor refractory to medical treatment
* Having not expressed their opposition, after being informed, to the reuse of their data for the purposes of this research.

Exclusion criteria:

* Subject who expressed their opposition to participating in the study
* Patient already included in another ongoing study
* Subject under guardianship or curatorship
* Subject under safeguard of justice

Primary outcomes:
measure: Progression-free survival assessed using RECIST(Response evaluation criteria in solid tumors) criteria
timeFrame: at 6 months after cryoablation
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'Imagerie Interventionnelle - CHU de Strasbourg - France
Study officials:
References: